Language:

Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis

Indian journal of ophthalmology, 2020-09, Vol.68 (9), p.1912-1915 [Peer Reviewed Journal]

COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd. ;2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Copyright: © 2020 Indian Journal of Ophthalmology 2020 ;ISSN: 0301-4738 ;EISSN: 1998-3689 ;DOI: 10.4103/ijo.IJO_439_20 ;PMID: 32823413

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis
Author: Kawali, Ankush ; Mohan, Ashwin ; Mehta, Ruchir ; Mahendradas, Padmamalini ; Srinivasan, Sanjay ; Shetty, Bhujang
Subjects: Acuity ; Angiogenesis Inhibitors - therapeutic use ; anti-vegf ; Bevacizumab - therapeutic use ; Care and treatment ; cystoid macular edema ; Development and progression ; Edema ; epidemic retinitis ; Epidemics ; Eye ; Genetic aspects ; Health aspects ; Humans ; Intravitreal Injections ; macular edema ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - epidemiology ; Original ; Ranibizumab - therapeutic use ; Retinal diseases ; Retinitis ; Retinitis - drug therapy ; retinitis post febrile illness ; Retrospective Studies ; Steroid hormones ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A
Is Part Of: Indian journal of ophthalmology, 2020-09, Vol.68 (9), p.1912-1915
Description: Purpose: To study efficacy of anti-vascular endothelial growth factor (anti-VEGF) in resolution of macular edema in epidemic retinitis (ER). Methods: In this retrospective, comparative study, patients diagnosed as ER with central macular thickness (CMT) ≥ 600 μm on SD-OCT at presentation were studied. Eyes which did not receive intravitreal anti-VEGF formed group A and eyes receiving additional anti-VEGF formed group B. Eyes receiving anti-VEGF monotherapy were studied separately. Cases with subsequent OCT scans with interval of more than 20 days and cases without OCT scan at the resolution were excluded. Treatment details, visual outcome, and days to resolution of macular edema were studied. Results: Mean CMT in group A (n = 8) was 820.1 μm (range 607-1004 μm) and in Group B (n = 4) was 756.0 μm (range 603-1000 μm). Macular edema resolved in 34.8 days (range: 16-65) and 39.0 days (range: 21-45) in group A and B, respectively. Two eyes with anti-VEGF monotherapy recovered in 45 and 18 days, respectively. Mean corrected distance visual acuity (CDVA) at presentation in group A was 19.1 (range: 0-61) ETDRS letters and in group B was 14.3 (range: 0-35) ETDRS letters. Mean CDVA improved to 65.7 (range: 0-85) and 50.8 (range: 20-76) ETDRS letters in group A and B, respectively. Anti-VEGF monotherapy eyes improved from 35 and 46 ETDRS letters to 70 and 85 ETDRS letters, respectively. Conclusion: Additional anti-VEGF therapy has no added advantage in speed of resolution of macular edema due to ER. A randomized controlled trial with steroids sparing "anti-VEGF monotherapy" may verify our observations.
Publisher: India: Wolters Kluwer India Pvt. Ltd
Language: English
Identifier: ISSN: 0301-4738
EISSN: 1998-3689
DOI: 10.4103/ijo.IJO_439_20
PMID: 32823413
Source: Open Access: DOAJ Directory of Open Access Journals
Open Access: PubMed Central
AUTh Library subscriptions: ProQuest Central
GFMER Free Medical Journals
MEDLINE
Medknow Medical Journals (Open access)

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Anti-vascular endothelial growth factor in the treatment of macular edema in epidemic retinitis

Searching Remote Databases, Please Wait